KAMES CAPITAL plc Boosts Position in Pfizer Inc. (PFE)
KAMES CAPITAL plc increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,350,166 shares of the biopharmaceutical company’s stock after buying an additional 8,381 shares during the period. KAMES CAPITAL plc’s holdings in Pfizer were worth $47,526,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in PFE. Mason Street Advisors LLC bought a new stake in Pfizer during the second quarter valued at about $28,763,000. Northwestern Mutual Wealth Management Co. boosted its stake in Pfizer by 3.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 348,938 shares of the biopharmaceutical company’s stock valued at $12,286,000 after buying an additional 13,072 shares during the period. Front Street Capital Management Inc. bought a new stake in Pfizer during the second quarter valued at about $277,000. Beacon Trust Co. boosted its stake in Pfizer by 0.7% in the second quarter. Beacon Trust Co. now owns 177,366 shares of the biopharmaceutical company’s stock valued at $6,245,000 after buying an additional 1,224 shares during the period. Finally, Harbour Capital Advisors LLC bought a new stake in Pfizer during the second quarter valued at about $481,000. 69.73% of the stock is owned by institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.79% during trading on Friday, reaching $31.48. 24,156,427 shares of the company’s stock were exchanged. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39. The firm has a market capitalization of $191.03 billion, a price-to-earnings ratio of 31.61 and a beta of 0.90. The stock has a 50-day moving average price of $32.56 and a 200 day moving average price of $34.24.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by $0.01. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The company had revenue of $13.05 billion for the quarter, compared to analyst estimates of $13.05 billion. During the same period in the previous year, the business posted $0.60 EPS. The firm’s revenue for the quarter was up 7.9% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post $2.41 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.81%. Pfizer’s payout ratio is currently 106.20%.
Several equities research analysts have issued reports on the stock. Jefferies Group set a $34.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Friday, November 11th. Bank of America Corp. restated a “buy” rating and issued a $36.00 price target (down previously from $40.00) on shares of Pfizer in a report on Monday, November 7th. Atlantic Securities set a $35.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Thursday, November 3rd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, November 2nd. Finally, BMO Capital Markets lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $40.00 to $33.00 in a report on Wednesday, November 2nd. Thirteen analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $37.74.
In other news, insider Albert Bourla sold 18,390 shares of Pfizer stock in a transaction on Friday, November 4th. The shares were sold at an average price of $30.05, for a total value of $552,619.50. Following the transaction, the insider now directly owns 149,199 shares of the company’s stock, valued at approximately $4,483,429.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anthony J. Maddaluna sold 10,000 shares of Pfizer stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the completion of the transaction, the insider now directly owns 112,087 shares in the company, valued at $3,698,871. The disclosure for this sale can be found here. Company insiders own 0.07% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.